Greenwich LifeSciences Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| 2023 | 2022 | |
|---|---|---|
| Operating activities: | ||
| Net loss | $(8,891,803) | $(7,825,237) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Amortization | 3,612 | 3,612 |
| Stock-based compensation | 2,378,088 | 1,743,865 |
| Changes in operating assets and liabilities: | ||
| Accounts payable | 35,472 | — |
| Unreimbursed expenses (accrued) | (3,971) | (122,267) |
| Net cash used in operating activities | (6,478,602) | (6,200,027) |
| Financing activities: | ||
| Repurchase of common stock via stock repurchase program, net of costs | — | (7,536,216) |
| Net cash provided by (used in) financing activities | — | (7,536,216) |
| Net increase (decrease) in cash | (6,478,602) | (13,736,243) |
| Cash, beginning of period | 13,468,026 | 27,204,269 |
| Cash, end of period | $6,989,424 | $13,468,026 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.